13/12/2023
Weβre excited to introduce Letibotulinumtoxin A, a breakthrough in the world of aesthetics. π Derived from Clostridium botulinum strain CBFC26, this new neurotoxin from Hugel, Inc. and CROMA Pharma has been proven highly effective in reducing glabellar line severity (GLS) in a recent Phase III clinical trial.
π Study Highlights:
π 78.6% of participants saw significant improvement at 4 weeks!
π Rapid onset: Subjects noticed results as early as Day 2.
π Long-lasting effects: The mean time until the first retreatment was an impressive 127.26 days.
π Safety first: Letibotulinumtoxin A was well-tolerated with a convincing safety profile.
Use our contact us page to ask us any questions!
#